Sequenta Presents Key Data at the 2011 American Society of Hematology Annual Meeting

SAN FRANCISCO, Dec 05, 2011 -- Sequenta, Inc., will present the results from five studies at the American Society of Hematology (ASH) annual meeting in San Diego, CA, December 10-12, 2011. The posters demonstrate significantly higher sensitivity of the company's Immune Cell Receptor Sequencing (ICRS) platform in detecting Minimal Residual Disease in Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma patient samples compared to standard of care technologies. The data presented also shows a significant correlation between the presence of these cells and clinical relapse.

Sequenta's five poster presentations at the ASH conference include data highlighting the use of noninvasive ICRS technology to accurately assess the disease state by counting cancer cells in circulation in four disease states.

The following poster presentations will be made during the conference by Sequenta and its collaborators:

About Sequenta Inc.Sequenta, Inc. is a privately held company developing and commercializing molecular diagnostic assays based on a proprietary sequencing approach to the profiling of T and B cell receptor repertoires. The incredible diversity created by these genes is at the heart of a large number of conditions critical to human health and disease.

The company was founded in 2008 by Tom Willis and Malek Faham, two entrepreneurs who previously founded ParAllele BioScience, a company that developed and commercialized genomic technologies. ParAllele was acquired by Affymetrix in 2005. Sequenta's investors include Mohr Davidow and Index Ventures. The company is based in San Francisco, Calif., More information can be found at www.sequentainc.com .